Introduction Endovascular treatment’s (EVT) safety and efficacy have been proven in treating acute ischemic stroke (AIS) due to large vessel occlusion (LVO). However, limited data exist in different stroke subtypes. We aimed to investigate the differences in efficacy and safety of EVT for acute LVO according to different stroke subtypes. Methods A total of 1635 AIS patients with LVO undergoing EVT from a prospective cohort of the Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke (ANGEL-ACT) registry were classified into three types according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. We compared the primary outcome: 90-day modified Rankin Scale (mRS) score, the secondary outcomes: 90-day mRS (0–1, 0–2, and 0–3), successful recanalization (mTICI 2b/3), and complete recanalization (mTICI 3), and the safety outcomes: death within 90 days, parenchymal hemorrhage (PH), and symptomatic intracranial hemorrhage (SICH) among the three subtypes of stroke patients. Then, multivariable logistic regression models adjusting for potential baseline-confounding variables to determine the associations between stroke subtypes and safety and efficacy endpoints were performed. Finally, we performed subgroup analyses to explore discrepancies in the relationships. Results EVT of cardioembolic LVO (CE-LVO) had a higher rate of mTICI 3 (71.7% vs. 65.9% and 63.2%; P = 0.024) and a higher rate of PH (13.8% vs. 5.4% and 6.7%; P < 0.001) when compared to other stroke subtypes. Even multivariable analysis demonstrated that CE-LVO was associated with mTICI 3 [adjusted odds ratio (OR), 1.50 (95% CI 1.04–2.17)] and PH [adjusted OR, 1.97 (95% CI 1.09–3.55)]. However, the 90-day mRS distribution and 90-day mRS (0–1, 0–2, and 0–3) did not differ among the stroke subtypes, and nor did the SICH ( P > 0.05). Conclusions Functional outcomes were similar among different stroke subtypes. Despite a higher rate of complete recanalization, there is an increased risk of parenchymal hemorrhage in CE-LVO. Trial Registration Clinical trial registration number: NCT03370939.
Direct oral anticoagulant (DOAC) reversal before intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients is well-documented in Europe, specifically for dabigatran: the selective humanized monoclonal antibody fragment idarucizumab, given to neutralize dabigatran prior to IVT, was associated with improved outcomes post-IVT. However, in the United States, this approach is rarely reported and not endorsed by guidelines. Therefore, further reporting on this is needed and neuroradiographic correlation may help validate this concept. At our hospital in Tampa, Florida, two octogenarians with atrial fibrillation, adherent with the DOAC dabigatran, presented with AIS shortly after symptom onset. Both received idarucizumab, then IVT. Clinical outcomes, treatment times, and perfusion-based neuroradiographic parameters were assessed. Patient A had a 41 ml penumbra on computed tomography perfusion (CTP) scan that decreased to 15 ml in final infarct volume on follow-up imaging, resulting in a 26 ml penumbral salvage (63.4%), and National Institutes of Health Stroke Scale (NIHSS) improved from 11 to 9 . Patient B had a 23 ml penumbra on CTP that decreased to 0.5 ml on follow-up imaging, resulting in a 22.5 ml penumbral salvage (97.8%), and NIHSS improved from 9 to 4. Neither developed bleeding complications. Both had delayed door-to-needle times but nevertheless demonstrated clinical neurological improvements.In our limited experience, IVT after immediate DOAC reversal in AIS patients on dabigatran was associated with clinical improvement in NIHSS by 2 to 5 points (with no neuroworsening), and penumbral salvage of ischemic brain tissue on neuroimaging ranging from 63.4% to 97.8%. Further reporting on this may lead to greater IVT use and better outcomes in "DOAC failures", especially for patients without other acute treatment options such as mechanical thrombectomy. Research into other anticoagulant reversal agents pre-IVT in AIS is also warranted.
Middle cerebral artery (MCA) duplication is a rare anatomical arrangement where an anomalous MCA arises from the distal end of the internal carotid artery. If occluded, a duplicated MCA can present with significant deficits comparable to an occlusion of the M2 vessel without obvious findings on vessel imaging via computed tomography angiography (CTA) or magnetic resonance angiography.A female in her 30s with no past medical history presented with suspected acute stroke 8 hours after last known normal-featuring new-onset right-sided weakness, facial droop, and slurred speech, which corresponds to a National Institutes of Health Stroke Scale score of 13. Head CTA was interpreted as preserved patency of intracranial vessels. CT perfusion was suggestive of a large area of penumbra. Emergent cerebral angiography demonstrated MCA duplication on the left side with proximal occlusion of the M1 branch supplying the traditional M2 territory. Mechanical thrombectomy achieved grade TICI 2b reperfusion. Throughout her hospital stay, her aphasia started to resolve, and the patient was discharged to inpatient rehabilitation. This case presents a diagnostic challenge and learning point in identifying similar patients in the future. We suggest the clinician, given a high clinical suspicion for large vessel occlusion, even if CTA is negative, to continue with CT perfusion to not miss stroke in patients with MCA duplication. If CT perfusion shows substantial deficit in an MCA distribution, one must consider that the patient may have an MCA duplication.
A 67-year-old man presented with dysphagia, hoarseness, dysarthria, left ptosis, and 30-pound weight loss over 7 months, requiring a percutaneous endoscopic gastrostomy (PEG) tube. Examination revealed partial left ptosis, dysphonia, left hemitongue weakness, atrophy, and fasciculations, and left hemipalate weakness (figure 1). Neurosurgery was consulted for high cervical osteophyte resection. Intraoperatively, the left carotid sheath and hypoglossal nerve were impinged by C1-2 osteophyte (figure 2A). The osteophyte was resected (figure 2B). 1,2
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.